Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker...

Keywords

MedicinePembrolizumabInternal medicineResponse Evaluation Criteria in Solid TumorsOncologyCohortMesotheliomaBiomarkerClinical endpointProspective cohort studyCancerProgressive diseaseDiseaseImmunotherapyPathologyClinical trial

Affiliated Institutions

Related Publications

Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro).

Rina Hui , Leena Gandhi , Enric Carcereny +17 more

9026 Background: The anti–PD-1 antibody pembro (MK-3475) is approved in the US for treating PD-L1–positive NSCLC that progressed after platinum-containing chemotherapy. This app...

2016 Journal of Clinical Oncology 58 citations

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi , Delvys Rodríguez‐Abreu , Shirish M. Gadgeel +26 more

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...

2018 New England Journal of Medicine 6245 citations

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer

Charlotte Roach , Nancy Zhang , Ellie Corigliano +7 more

A companion diagnostic assay was codeveloped by Dako for pembrolizumab non–small-cell lung cancer clinical trials to detect PD-L1 expression by immunohistochemistry (IHC). This ...

2016 Applied immunohistochemistry & molecu... 346 citations

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Sanjeev Mariathasan , Shannon J. Turley , Dorothee Nickles +39 more

2018 Nature 5078 citations

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

Publication Info

Year: 2020
Type: article
Volume: 21
Issue: 10
Pages: 1353-1365
Citations: 2300
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2300

OpenAlex

Cite This

APA Style

                            
                                
                                    Aurélien Marabelle, 
                                
                                    Marwan Fakih, 
                                
                                    Juanita Lopez
                                
                                et al.
                            
                            (2020). 
                            Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. 
                            The Lancet Oncology
                            , 21
                            (10)
                            , 1353-1365.
                            https://doi.org/10.1016/s1470-2045(20)30445-9
                        

Identifiers

DOI: 10.1016/s1470-2045(20)30445-9